Labeling Monoclonal Antibody with α-emitting (211)At at High Activity Levels via a Tin Precursor

Background: In a previous clinical study, the authors evaluated the potential of antitenascin C monoclonal antibody (mAb) 81C6 labeled with (211)At via the prosthetic agent N-succinimidyl 3-[(211)At]astatobenzoate (SAB) for the treatment of primary brain tumors. Although encouraging results were obt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biother Radiopharm
Main Authors: Vaidyanathan, Ganesan, Pozzi, Oscar R., Choi, Jaeyeon, Zhao, Xiao-Guang, Murphy, Shawn, Zalutsky, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475101/
https://ncbi.nlm.nih.gov/pubmed/32109139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2019.3204
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados